Meeting
2013 ASCO Annual Meeting
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Presenter
Richard G. Gray, MA, MSc
University of Oxford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Plenary Session
Session Title
Plenary Session Including FDA Commissioner Address, Public Service Award, and Science of Oncology Award and Lecture
Track
Special Sessions,Core Sessions
Sub Track
ER+
Clinical Trial Registration Number
ISRCTN17222211
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5)
DOI
10.1200/jco.2013.31.18_suppl.5
Abstract #
5
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
Speaker: Stephanie L. Graff, MD
Videos & Slides
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
Speaker: Thomas Meyskens
Videos & Slides
2012 ASCO Annual Meeting
Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen.
Speaker: Vincent O. Dezentje, MD
Videos & Slides
2011 ASCO Annual Meeting
ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.
Speaker: Mark Bouzyk, PhD